脑心通胶囊对原发性高血压患者疗效、血管内皮功能、血脂和炎性因子的影响
|
摘要
目的观察脑心通胶囊对原发性高血压患者疗效、血管内皮功能、血脂和炎性因子的影响。方法选择2017年3月—2018年3月收治的108例原发性高血压患者,按照用药方法不同分为观察组55例与对照组53例。对照组给予苯磺酸氨氯地平片治疗,观察组在对照组基础上联合脑心通胶囊。观察2组降压总有效率和不良反应总发生率,并比较治疗前后的一氧化氮(NO)、内皮素-1(ET-1)、总胆固醇(TC)、甘油三酯(TG)、白介素-6(IL-6)、超敏C反应蛋白(hs-CRP)水平。结果观察组降压总有效率高于对照组(P<0.05)。治疗后,2组NO水平高于治疗前,ET-1水平低于治疗前(P<0.01)。观察组治疗后NO水平高于对照组,ET-1水平低于对照组(P<0.01)。治疗后,观察组TC、TG、IL-6和hs-CRP水平低于治疗前和对照组(P<0.05,P<0.01)。2组不良反应总发生率比较差异无统计学意义(P>0.05)。结论脑心通胶囊对原发性高血压患者疗效肯定,能改善患者血管内皮功能、调节血脂、抑制炎性因子,且安全可靠。
Objective To observe effects of Naoxintong Capsule on efficacy, vascular endothelial functions, blood lipids and inflammatory factors of patients with essential hypertension. Methods A total of 108 patients with essential hypertension admitted during March 2017 and March 2018 were divided into observation group(n=55) and control group(n=53) according to different medication methods. Control group was treated with Amlodipine Besylate Tablets, while observation group was added with Naoxintong Capsules on the basis of treatment for control group. In two groups, the total effective rate of reducing blood pressure and the total incidence rate of adverse reactions were observed, and levels of nitric oxide(NO), endothelin-1(ET-1), total cholesterol(TC), triglyceride(TG), interleukin-6(IL-6) and hypersensitive C-reactive protein(hs-CRP) were compared before and after treatment. Results The total effective rate of reducing blood pressure in observation group was significantly higher than that in control group(P<0.05). After treatment, NO levels were significantly higher, while ET-1 levels were significantly lower than those before treatment in two groups(P<0.01). After treatment in observation group, NO level was significantly higher, while ET-1 level was significantly lower than those in control group(P<0.01). After treatment, TC, TG, IL-6 and hs-CRP levels in observation group were significantly lower than those before treatment in the same group and in control group(P<0.05, P<0.01). There was no significant difference in the total incidence rate of adverse reactions between two groups(P>0.05). Conclusion Naoxintong capsule has a definite curative effect in treatment of patients with essential hypertension, and it may improve vascular endothelial function, regulate blood lipid and inhibit inflammatory factors with safe and reliable.
Objective To observe effects of Naoxintong Capsule on efficacy, vascular endothelial functions, blood lipids and inflammatory factors of patients with essential hypertension. Methods A total of 108 patients with essential hypertension admitted during March 2017 and March 2018 were divided into observation group(n=55) and control group(n=53) according to different medication methods. Control group was treated with Amlodipine Besylate Tablets, while observation group was added with Naoxintong Capsules on the basis of treatment for control group. In two groups, the total effective rate of reducing blood pressure and the total incidence rate of adverse reactions were observed, and levels of nitric oxide(NO), endothelin-1(ET-1), total cholesterol(TC), triglyceride(TG), interleukin-6(IL-6) and hypersensitive C-reactive protein(hs-CRP) were compared before and after treatment. Results The total effective rate of reducing blood pressure in observation group was significantly higher than that in control group(P<0.05). After treatment, NO levels were significantly higher, while ET-1 levels were significantly lower than those before treatment in two groups(P<0.01). After treatment in observation group, NO level was significantly higher, while ET-1 level was significantly lower than those in control group(P<0.01). After treatment, TC, TG, IL-6 and hs-CRP levels in observation group were significantly lower than those before treatment in the same group and in control group(P<0.05, P<0.01). There was no significant difference in the total incidence rate of adverse reactions between two groups(P>0.05). Conclusion Naoxintong capsule has a definite curative effect in treatment of patients with essential hypertension, and it may improve vascular endothelial function, regulate blood lipid and inhibit inflammatory factors with safe and reliable.
引文
[1] 楚洁,王临虹,徐爱强,等.山东省成年人高血压与高血压前期流行情况及影响因素分析[J].中华预防医学杂志,2014,48(1):12-17.
[2] 刘璠,丁秀婷.高血压药物治疗方式及常用药物研究进展[J].中国药业,2015,24(23):253-255.
[3] 王磊,魏新伟,于芳.不同降压药物联合治疗对老年高血压患者血压变异性的影响[J].天津医药,2016,44(1):105-109.
[4] 陆建方,谭建华,邹永强.常用三类抗高血压药物不良反应监测分析[J].心脑血管病防治,2014,14(5):401-403.
[5] 赵涛,王一民,刘娜,等.从补阳还五汤到脑心通胶囊——脑心同治的思路探讨[J].世界中西医结合杂志,2012,7(10):900-903.
[6] 中国高血压防治指南修订委员会.中国高血压防治指南2010[J].中华心血管病杂志,2011,39(7):579-616.
[7] 陈岚,任骞,徐进,等.苯磺酸左旋氨氯地平对原发性高血压患者血管内皮功能的影响[J].陕西医学杂志,2016,45(2):241-242.
[8] 徐莉,王唯,李希辉,等.清眩降压汤对原发性高血压患者肾素-血管紧张素-醛固酮系统的影响[J].中国中西医结合急救杂志,2017,24(5):532-535.
[9] 项静,李志农,张镝.健脾平肝降压汤联合西药治疗高血压的效果观察[J].陕西中医,2016,37(4):426-427.
[10] 王玉民,范军铭.高血压病中医病机探讨[J].中医研究,2014,27(4):6-8.
[11] 吴娇,王聪.黄芪的化学成分及药理作用研究进展[J].新乡医学院学报,2018,35(9):755-760.
[12] 李伟霞,张书琦,赵艺丹,等.脑心通胶囊化学成分、药理作用及临床应用研究进展[J].中国中药杂志,2018,43(10):1998-2005.
[13] 赵步长,伍海勤,赵涛,等.中药复方脑心通胶囊类他汀作用研究概述[J].中国医药导报,2016,13(18):49-53.
[14] 彭代平,汤小虎,周瑞彬.桂枝温通经脉配伍对胶原诱导性关节炎大鼠的免疫调节作用[J].中国中西医结合杂志,2017,37(7):813-818.
[15] 刘暖,毛秉豫,杨雷,等.黄芪提取物对大鼠骨髓源性内皮祖细胞的作用[J].天津医药,2015,43(10):1093-1096,插1.
[16] 黄丹,文国强,黄影柳.脑心通对脑梗死患者血流动力学、血凝及纤溶系统的影响[J].辽宁中医杂志,2018,45(2):310-312.
[17] 王燕,李琳,丛伟红,等.原发性高血压与血管内皮功能的相关性分析[J].世界中西医结合杂志,2016,11(3):395-399
[18] 裴静静,沈小梅.原发性高血压病人血管内皮功能障碍的危险因素分析[J].中西医结合心脑血管病杂志,2016,14(9):992-996.
[19] 罗远,岳桂华,赵晓芳,等.芪七连胶囊对自发性高血压大鼠血管保护作用的实验研究[J].中成药,2015,37(2):260-264.
[20] 仲米存,苏晓慧,孔祥英,等.川芎嗪对大鼠脑微血管内皮细胞迁移及管腔形成的影响[J].中国实验方剂学杂志,2015,21(6):103-107.
[21] 李平.步长脑心通胶囊对慢性心衰患者心肌功能及血管内皮功能的影响[J].中国处方药,2016,14(10):81-82.
[22] 黄霞,苏高翔,杨日华,等.脑心通胶囊对冠状动脉临界病变冠心病患者炎症因子及疗效的影响[J].广东医学院学报,2016,34(5):450-452.
[23] 刘晓亚,房丹.中药全蝎药理作用研究进展[J].内蒙古中医药,2014,33(14):114-116.
[24] 梅琼,李全胜,张静,等.当归川芎组合对血脂及冠状动脉组织结构影响的实验研究[J].湖北中医药大学学报,2015,17(5):47-49.
[25] 明荷,谢寒,艾坤.复方丹参注射液联合针灸治疗对类风湿关节炎患者炎性因子和血脂水平的影响[J].中国老年学杂志,2016,36(11):2719-2721.
[26] 师帅,褚瑜光,宋庆桥,等.脑心通胶囊治疗冠心病合并高脂血症的系统评价[J].中国循证心血管医学杂志,2018,10(5):533-537.
[27] 王海燕,周惠芬,何昱,等.脑心通胶囊对缺糖缺氧损伤脑微血管内皮细胞的保护作用及其机制[J].中草药,2018,49(14):3318-3325.
[2] 刘璠,丁秀婷.高血压药物治疗方式及常用药物研究进展[J].中国药业,2015,24(23):253-255.
[3] 王磊,魏新伟,于芳.不同降压药物联合治疗对老年高血压患者血压变异性的影响[J].天津医药,2016,44(1):105-109.
[4] 陆建方,谭建华,邹永强.常用三类抗高血压药物不良反应监测分析[J].心脑血管病防治,2014,14(5):401-403.
[5] 赵涛,王一民,刘娜,等.从补阳还五汤到脑心通胶囊——脑心同治的思路探讨[J].世界中西医结合杂志,2012,7(10):900-903.
[6] 中国高血压防治指南修订委员会.中国高血压防治指南2010[J].中华心血管病杂志,2011,39(7):579-616.
[7] 陈岚,任骞,徐进,等.苯磺酸左旋氨氯地平对原发性高血压患者血管内皮功能的影响[J].陕西医学杂志,2016,45(2):241-242.
[8] 徐莉,王唯,李希辉,等.清眩降压汤对原发性高血压患者肾素-血管紧张素-醛固酮系统的影响[J].中国中西医结合急救杂志,2017,24(5):532-535.
[9] 项静,李志农,张镝.健脾平肝降压汤联合西药治疗高血压的效果观察[J].陕西中医,2016,37(4):426-427.
[10] 王玉民,范军铭.高血压病中医病机探讨[J].中医研究,2014,27(4):6-8.
[11] 吴娇,王聪.黄芪的化学成分及药理作用研究进展[J].新乡医学院学报,2018,35(9):755-760.
[12] 李伟霞,张书琦,赵艺丹,等.脑心通胶囊化学成分、药理作用及临床应用研究进展[J].中国中药杂志,2018,43(10):1998-2005.
[13] 赵步长,伍海勤,赵涛,等.中药复方脑心通胶囊类他汀作用研究概述[J].中国医药导报,2016,13(18):49-53.
[14] 彭代平,汤小虎,周瑞彬.桂枝温通经脉配伍对胶原诱导性关节炎大鼠的免疫调节作用[J].中国中西医结合杂志,2017,37(7):813-818.
[15] 刘暖,毛秉豫,杨雷,等.黄芪提取物对大鼠骨髓源性内皮祖细胞的作用[J].天津医药,2015,43(10):1093-1096,插1.
[16] 黄丹,文国强,黄影柳.脑心通对脑梗死患者血流动力学、血凝及纤溶系统的影响[J].辽宁中医杂志,2018,45(2):310-312.
[17] 王燕,李琳,丛伟红,等.原发性高血压与血管内皮功能的相关性分析[J].世界中西医结合杂志,2016,11(3):395-399
[18] 裴静静,沈小梅.原发性高血压病人血管内皮功能障碍的危险因素分析[J].中西医结合心脑血管病杂志,2016,14(9):992-996.
[19] 罗远,岳桂华,赵晓芳,等.芪七连胶囊对自发性高血压大鼠血管保护作用的实验研究[J].中成药,2015,37(2):260-264.
[20] 仲米存,苏晓慧,孔祥英,等.川芎嗪对大鼠脑微血管内皮细胞迁移及管腔形成的影响[J].中国实验方剂学杂志,2015,21(6):103-107.
[21] 李平.步长脑心通胶囊对慢性心衰患者心肌功能及血管内皮功能的影响[J].中国处方药,2016,14(10):81-82.
[22] 黄霞,苏高翔,杨日华,等.脑心通胶囊对冠状动脉临界病变冠心病患者炎症因子及疗效的影响[J].广东医学院学报,2016,34(5):450-452.
[23] 刘晓亚,房丹.中药全蝎药理作用研究进展[J].内蒙古中医药,2014,33(14):114-116.
[24] 梅琼,李全胜,张静,等.当归川芎组合对血脂及冠状动脉组织结构影响的实验研究[J].湖北中医药大学学报,2015,17(5):47-49.
[25] 明荷,谢寒,艾坤.复方丹参注射液联合针灸治疗对类风湿关节炎患者炎性因子和血脂水平的影响[J].中国老年学杂志,2016,36(11):2719-2721.
[26] 师帅,褚瑜光,宋庆桥,等.脑心通胶囊治疗冠心病合并高脂血症的系统评价[J].中国循证心血管医学杂志,2018,10(5):533-537.
[27] 王海燕,周惠芬,何昱,等.脑心通胶囊对缺糖缺氧损伤脑微血管内皮细胞的保护作用及其机制[J].中草药,2018,49(14):3318-3325.